Ocumetics Technology Corp. (TSXV: OTC | OTCQB: OTCFF | FRA: 2QBO) announced today highly encouraging six-month postoperative results from the first group of patients in its first-in-human (FIH) clinical study of the Ocumetics Accommodating Intraocular Lens. The outcomes exceed expectations, with all patients experiencing continuing vision improvements and a strong safety profile.
Group One patients entered the study with very poor vision, including one individual considered legally blind. At six months post-surgery, patients continue to demonstrate improved vision and stable visual acuity. Anecdotally, all patients reported life-changing results, including the ability to read, drive, and live independently again.
“After six months, what stands out most is not just the clinical performance of the Ocumetics Lens, but the profound impact on patients’ quality of life,” said Dean Burns, President and CEO of Ocumetics. “We’re developing a technology that dramatically improves people’s quality of life and we couldn’t be happier.”
The Company continues to leverage surgeon feedback and patient experience into ongoing product enhancements. Updated lens refinements are currently in manufacturing and testing, supporting the planned initiation of Group Two surgeries.
“The measurable improvements in visual acuity and consistency we are seeing at six months give us tremendous confidence as we advance to the next phase of our clinical program,” added Burns. “We are not only validating our technology, we are demonstrating its real-world impact.”
Ocumetics will host a webinar on April 22, 2026 at 4:00 PM ET to discuss the results. Registration is available at www.ocumetics.com/webinar.
The Ocumetics Lens is designed to fit within the eye’s natural lens compartment and use the eye’s natural muscle activity to shift focus from distance to near, potentially eliminating the need for corrective lenses. The positive six-month results reinforce the expected performance of this accommodating intraocular lens technology and provide momentum for the next phase of the clinical program.
